肺动脉高压与CKD及ESRD患者死亡和心血管疾病:系统综述与荟萃分析
该系统综述与荟萃分析纳入16项观察性研究共7112例CKD或ESRD患者,肺动脉高压总体患病率为23%。肺动脉高压与CKD患者全因死亡风险(RR 1.44)及透析ESRD患者(RR 2.32)和肾移植患者(RR 2.08)全因死亡风险增加相关,并与心血管事件和心血管死亡风险增加相关。
要点
- 肺动脉高压在CKD和ESRD患者中患病率23%,与全因死亡风险增加相关。
- 透析ESRD患者合并肺动脉高压的全因死亡风险(RR 2.32)高于CKD 1-5期患者(RR 1.44)。
- 肺动脉高压与CKD和ESRD患者心血管事件及心血管死亡风险增加相关。
核心结论
- 肺动脉高压与CKD和ESRD患者死亡及心血管事件风险显著增加相关,透析ESRD患者风险高于CKD 1-5期患者。
研究设计与样本
- 系统综述与荟萃分析,纳入16项观察性研究,共7112例CKD或ESRD患者,采用亚组分析和荟萃回归。
主要发现
- 肺动脉高压总体患病率为23%。
- 肺动脉高压与CKD患者全因死亡风险增加相关(RR 1.44;95% CI 1.17-1.76)。
- 肺动脉高压与透析ESRD患者全因死亡风险增加相关(RR 2.32;95% CI 1.91-2.83)。
- 肺动脉高压与肾移植患者全因死亡风险增加相关(RR 2.08;95% CI 1.35-3.20)。
- 肺动脉高压与CKD患者心血管事件风险增加相关(RR 1.67;95% CI 1.07-2.60),与透析ESRD患者心血管事件风险增加相关(RR 2.33;95% CI 1.76-3.08),与CKD或ESRD患者心血管死亡风险增加相关(RR 2.20;95% CI 1.53-3.15)。
临床怎么用
- 对CKD和ESRD患者应关注肺动脉高压的存在,因其与死亡和心血管事件风险增加相关。
- 透析ESRD患者合并肺动脉高压时风险更高,需加强风险评估。
局限性
- 纳入研究存在异质性。
- 可能存在残余混杂。
- 缺乏个体患者水平数据。
- 可能存在结局报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension is common in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and may be associated with poor outcomes. The magnitude of the association between pulmonary hypertension and mortality is uncertain due to the small size and variable findings of observational studies. STUDY DESIGN: Systematic review and meta-analysis of observational studies using subgroup analyses and metaregression. SETTING & POPULATION: Patients with ESRD or earlier stages of CKD. SELECTION CRITERIA FOR STUDIES: Observational studies reporting clinical outcomes in patients with co-existing pulmonary hypertension and CKD or ESRD identified using a systematic search of PubMed and Embase. PREDICTOR: Pulmonary hypertension diagnosed by Doppler echocardiography. OUTCOMES: All-cause mortality, cardiovascular mortality, and cardiovascular events. RESULTS: 16 studies, with 7,112 patients with an overall pulmonary hypertension prevalence of 23%, were included. Pulmonary hypertension was associated with increased risk for all-cause mortality among patients with CKD (relative risk [RR], 1.44; 95% CI, 1.17-1.76), with ESRD receiving maintenance dialysis (RR, 2.32; 95% CI, 1.91-2.83), and with a functioning kidney transplant (RR, 2.08; 95% CI, 1.35-3.20). Pulmonary hypertension was associated with increased risk for cardiovascular events in patients with CKD (RR, 1.67; 95% CI, 1.07-2.60) and ESRD receiving dialysis (RR, 2.33; 95% CI, 1.76-3.08). There was an association between pulmonary hypertension and increased risk for cardiovascular mortality in patients with CKD or ESRD (RR, 2.20; 95% CI, 1.53-3.15). LIMITATIONS: Heterogeneity of included studies, possibility of residual confounding, unavailability of individual patient-level data, and possibility of outcome reporting bias. CONCLUSIONS: Pulmonary hypertension is associated with a substantially increased risk for death and cardiovascular events in patients with CKD and ESRD. Risk is higher in patients with ESRD receiving dialysis compared with patients with CKD stages 1 to 5. Understanding the effect of interventions to lower pulmonary artery pressure on the survival of these patents awaits their evaluation in randomized controlled trials.
引用
- Tang M, Batty JA, Lin C, et al. Pulmonary Hypertension, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2018. PMID: 29429751. doi:10.1053/j.ajkd.2017.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。